Nicotinamide Mononucleotide (NMN) continues to be at the forefront of anti-aging and longevity research, with several significant studies published in Q1 2026 providing new insights into its mechanisms of action and potential health benefits.
A landmark clinical trial published in Nature Aging demonstrated that daily NMN supplementation at 500mg significantly increased NAD+ levels in middle-aged adults within just two weeks. Participants also reported improvements in energy levels, sleep quality, and physical endurance after 12 weeks of supplementation.
Researchers at Tokyo University published findings showing NMN's potential role in supporting cardiovascular health. The study, conducted over 6 months, showed that NMN supplementation improved vascular function markers in adults aged 55-75, suggesting potential benefits for age-related cardiovascular decline.
In the field of metabolic health, a new study from Stanford University demonstrated that NMN supplementation improved insulin sensitivity in overweight adults. These findings align with earlier preclinical data and open new avenues for NMN applications in metabolic health management.
The global NMN market continues to expand rapidly, with estimated market size reaching $800 million in 2026. Key growth drivers include aging populations, increasing health consciousness, and growing scientific evidence supporting NMN's efficacy.
Hexia Biotechnology supplies pharmaceutical-grade NMN (≥99% purity) produced through advanced enzymatic biosynthesis technology. Our NMN products are backed by comprehensive certificates of analysis and are suitable for dietary supplement formulations worldwide.